Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis / 中华医学遗传学杂志
Chinese Journal of Medical Genetics
;
(6): 129-133, 2006.
Artículo
en Inglés
| WPRIM
| ID: wpr-263836
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride(RLX) on bone mineral density (BMD) and bone turnover markers in postmenopausal women with osteoporosis.</p><p><b>METHODS</b>A total of 68 unrelated postmenopausal women with osteoporosis of Han ethnicity aged 47-74 years were randomly divided into 2 groups of 34 women RLX group (60 mg were given daily for 12 months) and placebo group. BMD and bone turnover markers were measured at baseline, 6 and 12 months after treatment. The polymorphisms of Xba I and Pvu II sites in estrogen receptor 1 gene(ESR1), Ras I site in ESR2 gene, and start codon (Fok I) and CDX2 binding sites in vitamin D receptor gene (VDR) were analyzed.</p><p><b>RESULTS</b>A total of 58 patients completed 12 months of study period. By the end of study, the increased percentage of BMD in lumbar spine 2-4 (L2-4), total hip, and trochanter were found significantly different between RLX group and placebo group(P<0.05), and the decreased percentage of C-telopeptide and osteocalcin were significantly different between the two groups (P<0.01). The BMD of total hip and trochanter of women with FF genotypes of VDR Fok I site were decreased by 1.98%+/-4.86% and 2.26%+/-4.73% respectively in the RLX group, but those of women with Ff/ff genotypes were increased by 2.52%+/-2.75% and 2.74 %+/-2.97%, respectively(P<0.05). Moreover, the total hip BMD of women with PP/Pp genotypes of ESR1 Pvu II site was increased by 2.12%+/-2.78%, and of women with pp genotype it was decreased by 1.34%+/-3.73%(P<0.05). However, no significant association was observed of the polymorphisms of five sites with the changes of BMD and bone turnover markers in the placebo group.</p><p><b>CONCLUSION</b>The effect of RLX on BMD in postmenopausal women with osteoporosis is regulated by the polymorphisms of Fok I of VDR gene and Pvu II of ESR1 gene. The study is valuable to select this drug according to genotype of patients in clinical.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Osteoporosis
/
Farmacología
/
Polimorfismo Genético
/
Mujeres
/
Huesos
/
Enfermedades Óseas Metabólicas
/
Biomarcadores
/
Densidad Ósea
/
Osteoporosis Posmenopáusica
/
Método Doble Ciego
Tipo de estudio:
Ensayo Clínico Controlado
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Chinese Journal of Medical Genetics
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS